Table 1. Clinical history and laboratory data.

Patient	Age/Sex	Diagnosis	PD-(L)1 Immunotherapy	Prior Treatments	HbA1c (%)	Time after Anti-PD1 (days)	Prior Diabetes	Concomitant IRAEs
1	70M	Metastatic melanoma	Pembrolizumab	None	11.9	106	Yes	None
2	67M	Metastatic lung squamous cell carcinoma	Nivolumab	Gemcitabine Carboplatin Docetaxel Ipilimumab	9.2	388	No	None
3	49M	Metastatic lung adenocarcinoma	Nivolumab	Carboplatin Paclitaxel Bevacizumab	8.9	20	No	Encephalitis Pneumonitis Myocarditis
4	27M	Metastatic melanoma	Nivolumab	Ipilimumab	6.2	972	No	Adrenal insufficiency Transaminitis
5	74F	Metastatic lung squamous cell carcinoma	Nivolumab	Gemcitabine Carboplatin	9.3	620	No	Hypothyroidism